191 related articles for article (PubMed ID: 8787852)
1. Interstitial chemotherapy of experimental brain tumors: comparison of intratumoral injection versus polymeric controlled release.
Buahin KG; Brem H
J Neurooncol; 1995 Nov; 26(2):103-10. PubMed ID: 8787852
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas.
Judy KD; Olivi A; Buahin KG; Domb A; Epstein JI; Colvin OM; Brem H
J Neurosurg; 1995 Mar; 82(3):481-6. PubMed ID: 7861228
[TBL] [Abstract][Full Text] [Related]
3. Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors.
Sipos EP; Tyler B; Piantadosi S; Burger PC; Brem H
Cancer Chemother Pharmacol; 1997; 39(5):383-9. PubMed ID: 9054951
[TBL] [Abstract][Full Text] [Related]
4. Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: a novel treatment for experimental malignant glioma.
Rhines LD; Sampath P; DiMeco F; Lawson HC; Tyler BM; Hanes J; Olivi A; Brem H
Neurosurgery; 2003 Apr; 52(4):872-9; discussion 879-80. PubMed ID: 12657184
[TBL] [Abstract][Full Text] [Related]
5. Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain.
Tamargo RJ; Myseros JS; Epstein JI; Yang MB; Chasin M; Brem H
Cancer Res; 1993 Jan; 53(2):329-33. PubMed ID: 8417826
[TBL] [Abstract][Full Text] [Related]
6. Local delivery of minocycline and systemic BCNU have synergistic activity in the treatment of intracranial glioma.
Frazier JL; Wang PP; Case D; Tyler BM; Pradilla G; Weingart JD; Brem H
J Neurooncol; 2003 Sep; 64(3):203-9. PubMed ID: 14558595
[TBL] [Abstract][Full Text] [Related]
7. The role of minocycline in the treatment of intracranial 9L glioma.
Weingart JD; Sipos EP; Brem H
J Neurosurg; 1995 Apr; 82(4):635-40. PubMed ID: 7897527
[TBL] [Abstract][Full Text] [Related]
8. O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma.
Rhines LD; Sampath P; Dolan ME; Tyler BM; Brem H; Weingart J
Cancer Res; 2000 Nov; 60(22):6307-10. PubMed ID: 11103789
[TBL] [Abstract][Full Text] [Related]
9. Intralesionally implanted cisplatin plus systemic carmustine for the treatment of brain tumor in rats.
Kong Q; Kleinschmidt-DeMasters BK; Lillehei KO
J Surg Oncol; 1998 Oct; 69(2):76-82. PubMed ID: 9808509
[TBL] [Abstract][Full Text] [Related]
10. Increased tumor cures using combined radiosurgery and BCNU in the treatment of 9l glioma in the rat brain.
Khil MS; Kolozsvary A; Apple M; Kim JH
Int J Radiat Oncol Biol Phys; 2000 May; 47(2):511-6. PubMed ID: 10802380
[TBL] [Abstract][Full Text] [Related]
11. Injection of chemotherapeutic microspheres and glioma. IV: Eradicating tumors in rats.
Emerich DF; Winn SR; Bartus RT
Cell Transplant; 2002; 11(1):47-54. PubMed ID: 12095219
[TBL] [Abstract][Full Text] [Related]
12. Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.
Shapira-Furman T; Serra R; Gorelick N; Doglioli M; Tagliaferri V; Cecia A; Peters M; Kumar A; Rottenberg Y; Langer R; Brem H; Tyler B; Domb AJ
J Control Release; 2019 Feb; 295():93-101. PubMed ID: 30605703
[TBL] [Abstract][Full Text] [Related]
13. Resorbable polymer microchips releasing BCNU inhibit tumor growth in the rat 9L flank model.
Kim GY; Tyler BM; Tupper MM; Karp JM; Langer RS; Brem H; Cima MJ
J Control Release; 2007 Nov; 123(2):172-8. PubMed ID: 17884232
[TBL] [Abstract][Full Text] [Related]
14. Lactacystin exhibits potent anti-tumor activity in an animal model of malignant glioma when administered via controlled-release polymers.
Legnani FG; Pradilla G; Thai QA; Fiorindi A; Recinos PF; Tyler BM; Gaini SM; DiMeco F; Brem H; Olivi A
J Neurooncol; 2006 May; 77(3):225-32. PubMed ID: 16609837
[TBL] [Abstract][Full Text] [Related]
15. Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model.
Recinos VR; Tyler BM; Bekelis K; Sunshine SB; Vellimana A; Li KW; Brem H
Neurosurgery; 2010 Mar; 66(3):530-7; discussion 537. PubMed ID: 20173548
[TBL] [Abstract][Full Text] [Related]
16. DTI-015 produces cures in T9 gliosarcoma.
Pietronigro D; Drnovsky F; Cravioto H; Ransohoff J
Neoplasia; 2003; 5(1):17-22. PubMed ID: 12659666
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of in vitro and in vivo antitumor activity of BCNU-loaded PLGA wafer against 9L gliosarcoma.
Lee JS; An TK; Chae GS; Jeong JK; Cho SH; Lee HB; Khang G
Eur J Pharm Biopharm; 2005 Jan; 59(1):169-75. PubMed ID: 15567315
[TBL] [Abstract][Full Text] [Related]
18. Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma.
Storm PB; Renard VM; Moriarity JL; Tyler B; Wilentz RE; Brem H; Weingart JD
Cancer Chemother Pharmacol; 2004 Oct; 54(4):361-7. PubMed ID: 15197484
[TBL] [Abstract][Full Text] [Related]
19. Local delivery of interleukin-2 and adriamycin is synergistic in the treatment of experimental malignant glioma.
Hsu W; Lesniak MS; Tyler B; Brem H
J Neurooncol; 2005 Sep; 74(2):135-40. PubMed ID: 16193383
[TBL] [Abstract][Full Text] [Related]
20. Local delivery of the topoisomerase I inhibitor camptothecin sodium prolongs survival in the rat intracranial 9L gliosarcoma model.
Weingart JD; Thompson RC; Tyler B; Colvin OM; Brem H
Int J Cancer; 1995 Sep; 62(5):605-9. PubMed ID: 7665233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
